[1] P. W. Sheard and R. D. Anderson, “Age-related loss of muscle fibres is highly variable amongst mouse skeletal muscles,” Bio- gerontology, vol. 13, no. 2, pp. 157–167, 2012.
[2] S. Schiaffino, K. A. Dyar, S. Ciciliot, B. Blaauw, and M. Sandri, “Mechanisms regulating skeletal muscle growth and atrophy,” The FEBS Journal, vol. 280, no. 17, pp. 4294–4314, 2013.
[3] A. Inoue, X. W. Cheng, Z. Huang et al., “Exercise restores mus- cle stem cell mobilization, regenerative capacity and muscle metabolic alterations via adiponectin/AdipoR1 activation in SAMP10 mice,” Journal of Cachexia, Sarcopenia and Muscle, vol. 8, no. 3, pp. 370–385, 2017.
[4] A. M. Sanchez, R. B. Candau, and H. Bernardi, “FoxO tran- scription factors: their roles in the maintenance of skeletal muscle homeostasis,” Cellular and Molecular Life Sciences, vol. 71, no. 9, pp. 1657–1671, 2014.
[5] S. T. Arthur and I. D. Cooley, “The effect of physiological stim- uli on sarcopenia; impact of Notch and Wnt signaling on impaired aged skeletal muscle repair,” International Journal of Biological Sciences, vol. 8, no. 5, pp. 731–760, 2012.
[6] B. C. Yaden, Y. X. Wang, J. M. Wilson et al., “Inhibition of acti- vin A ameliorates skeletal muscle injury and rescues contrac- tile properties by inducing efficient remodeling in female mice,” The American Journal of Pathology, vol. 184, no. 4, pp. 1152–1166, 2014.
[7] N. Liu, B. R. Nelson, S. Bezprozvannaya et al., “Requirement of MEF2A, C, and D for skeletal muscle regeneration,” Proceed- ings of the National Academy of Sciences of the United States of America, vol. 111, no. 11, pp. 4109–4114, 2014.
[8] S. Ogasawara, X. W. Cheng, A. Inoue et al., “Cathepsin K activity controls cardiotoxin-induced skeletal muscle repair in mice,” Journal of Cachexia, Sarcopenia and Muscle, vol. 9, no. 1, pp. 160–175, 2018.
[9] J. D. Bernet, J. D. Doles, J. K. Hall, K. Kelly Tanaka, T. A. Carter, and B. B. Olwin, “p38 MAPK signaling underlies a cell- autonomous loss of stem cell self- renewal in skeletal muscle of aged mice,” Nature Medicine, vol. 20, no. 3, pp. 265–271, 2014.
[10] M. T. Tierney, T. Aydogdu, D. Sala et al., “STAT3 signaling controls satellite cell expansion and skeletal muscle repair,” Nature Medicine, vol. 20, no. 10, pp. 1182–1186, 2014.
[11] L. Lukjanenko, M. J. Jung, N. Hegde et al., “Loss of fibronectin from the aged stem cell niche affects the regenerative capacity of skeletal muscle in mice,” Nature Medicine, vol. 22, no. 8, pp. 897–905, 2016.
[12] C. Linard, M. Brachet, B. L’homme et al., “Long-term effective- ness of local BM-MSCs for skeletal muscle regeneration: a proof of concept obtained on a pig model of severe radiation burn,” Stem Cell Research & Therapy, vol. 9, no. 1, p. 299, 2018.
[13] K. Archacka, I. Grabowska, B. Mierzejewski et al., “Hypoxia preconditioned bone marrow-derived mesenchymal stromal/- stem cells enhance myoblast fusion and skeletal muscle regen- eration,” Stem Cell Research & Therapy, vol. 12, no. 1, p. 448, 2021.
[14] R. Squecco, A. Tani, F. Chellini et al., “Bone marrow- mesenchymal stromal cell secretome as conditioned medium relieves experimental skeletal muscle damage induced by ex vivo eccentric contraction,” International Journal of Molec- ular Sciences, vol. 22, no. 7, p. 3645, 2021.
[15] X. Liu, L. Zheng, Y. Zhou, Y. Chen, P. Chen, and W. Xiao, “BMSC transplantation aggravates inflammation, oxidative stress, and fibrosis and impairs skeletal muscle regeneration,” Frontiers in Physiology, vol. 10, p. 87, 2019.
[16] D. R. Lemos, F. Babaeijandaghi, M. Low et al., “Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF- mediated apoptosis of fibro/adipogenic progenitors,” Nature Medicine, vol. 21, no. 7, pp. 786–794, 2015.
[17] B. D. Cosgrove, P. M. Gilbert, E. Porpiglia et al., “Rejuvenation of the muscle stem cell population restores strength to injured aged muscles,” Nature Medicine, vol. 20, no. 3, pp. 255–264, 2014.
[18] B. Benoit, E. Meugnier, M. Castelli et al., “Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates mus- cle wasting in mice,” Nature Medicine, vol. 23, no. 8, pp. 990– 996, 2017.
[19] E. P. Brass and K. E. Sietsema, “Considerations in the develop- ment of drugs to treat sarcopenia,” Journal of the American Geriatrics Society, vol. 59, no. 3, pp. 530–535, 2011.
[20] M. Brotto and E. L. Abreu, “Sarcopenia: pharmacology of today and tomorrow,” The Journal of Pharmacology and Experimental Therapeutics, vol. 343, no. 3, pp. 540–546, 2012.
[21] D. I. Linzer, S. J. Lee, L. Ogren, F. Talamantes, and D. Nathans, “Identification of proliferin mRNA and protein in mouse pla- centa,” Proceedings of the National Academy of Sciences of the United States of America, vol. 82, no. 13, pp. 4356–4359, 1985.
[22] Y. Fang, P. Lepont, J. T. Fassett et al., “Signaling between the placenta and the uterus involving the mitogen-regulated pro- tein/proliferins,” Endocrinology, vol. 140, no. 11, pp. 5239–5249, 1999.
[23] A. M. Corbacho, G. Martinez De La Escalera, and C. Clapp, “Roles of prolactin and related members of the prolactin/- growth hormone/placental lactogen family in angiogenesis,” The Journal of Endocrinology, vol. 173, no. 2, pp. 219–238, 2002.
[24] J. T. Nelson, N. Rosenzweig, and M. Nilsen-Hamilton, “Characterization of the mitogen-regulated protein (proliferin) receptor,” Endocrinology, vol. 136, no. 1, pp. 283–288, 1995.
[25] H. M. El-Shewy and L. M. Luttrell, “Chapter 24 Insulin‐Like Growth Factor‐2/Mannose‐6 Phosphate Receptors,” Vitamins and Hormones, vol. 80, pp. 667–697, 2009.
[26] D. J. Toft, S. B. Rosenberg, G. Bergers, O. Volpert, and D. I. Linzer, “Reactivation of proliferin gene expression is associ- ated with increased angiogenesis in a cell culture model of fibrosarcoma tumor progression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 23, pp. 13055–13059, 2001.
[27] S. J. Lee and D. Nathans, “Proliferin secreted by cultured cells binds to mannose 6-phosphate receptors.,” The Journal of Bio- logical Chemistry, vol. 263, no. 7, pp. 3521–3527, 1988.
[28] V. Leksa, K. Pfisterer, G. Ondrovicova et al., “Dissecting Man- nose 6-Phosphate-Insulin-like Growth Factor 2 Receptor Complexes That Control Activation and Uptake of Plasmino-gen in Cells∗,” The Journal of Biological Chemistry, vol. 287, no. 27, pp. 22450–22462, 2012.
[29] J. C. Groskopf, L. J. Syu, A. R. Saltiel, and D. I. Linzer, “Prolif- erin induces endothelial cell chemotaxis through a G protein- coupled, mitogen-activated protein kinase-dependent path- way,” Endocrinology, vol. 138, no. 7, pp. 2835–2840, 1997.
[30] D. Jackson, O. V. Volpert, N. Bouck, and D. I. Linzer, “Stimu- lation and inhibition of angiogenesis by placental proliferin and proliferin-related protein,” Science, vol. 266, no. 5190, pp. 1581–1584, 1994.
[31] X. Yang, D. Qiao, K. Meyer, T. Pier, S. Keles, and A. Friedl, “Angiogenesis Induced by Signal Transducer and Activator of Transcription 5A (STAT5A) Is Dependent on Autocrine Activity of Proliferin,” The Journal of Biological Chemistry, vol. 287, no. 9, pp. 6490–6502, 2012.
[32] L. Hu, Z. Huang, H. Ishii et al., “PLF-1 (proliferin-1) modu- lates smooth muscle cell proliferation and development of experimental intimal hyperplasia,” Journal of the American Heart Association, vol. 8, no. 24, article e005886, 2019.
[33] L. Piao, G. Zhao, E. Zhu et al., “Chronic psychological stress accelerates vascular senescence and impairs ischemia- induced neovascularization: the role of dipeptidyl peptidase- 4/glucagon-like peptide-1-adiponectin axis,” Journal of the American Heart Association, vol. 6, no. 10, 2017.
[34] L. Piao, C. Yu, W. Xu et al., “Adiponectin/AdiopR1 signal inactivation contributes to impaired angiogenesis in mice of advanced age,” International Journal of Cardiology, vol. 267, pp. 150–155, 2018.
[35] H. Jiang, X. Wu Cheng, G. P. Shi et al., “Cathepsin K-mediated Notch1 activation contributes to neovascularization in response to hypoxia,” Nature Communications, vol. 5, no. 1, p. 3838, 2014.
[36] X. Meng, L. Piao, H. Wang et al., “Deficiency of cysteinyl cathepsin K suppresses the development of experimental inti- mal hyperplasia in response to chronic stress,” Journal of Hypertension, vol. 38, no. 8, pp. 1514–1524, 2020.
[37] F. Kim, M. Pham, I. Luttrell et al., “Toll-like receptor-4 medi- ates vascular inflammation and insulin resistance in diet- induced obesity,” Circulation Research, vol. 100, no. 11, pp. 1589–1596, 2007.
[38] A. E. Mullick, P. S. Tobias, and L. K. Curtiss, “Modulation of atherosclerosis in mice by Toll-like receptor 2,” The Jour- nal of Clinical Investigation, vol. 115, no. 11, pp. 3149–3156, 2005.
[39] Y. Sun, M. Ishibashi, T. Seimon et al., “Free cholesterol accu- mulation in macrophage membranes activates Toll-like recep- tors and p38 mitogen-activated protein kinase and induces cathepsin K,” Circulation Research, vol. 104, no. 4, pp. 455– 465, 2009.
[40] I. Lahmann, J. Griger, J. S. Chen, Y. Zhang, M. Schuelke, and C. Birchmeier, “Met and Cxcr4 cooperate to protect skeletal muscle stem cells against inflammation-induced damage dur- ing regeneration,” eLife, vol. 10, 2021.
[41] J. Fang, J. Sia, J. Soto et al., “Skeletal muscle regeneration via the chemical induction and expansion of myogenic stem cells in situ or in vitro,” Nature Biomedical Engineering, vol. 5, no. 8, pp. 864–879, 2021.
[42] C. Leung, K. B. A. Murad, A. L. T. Tan et al., “Lgr5 marks adult progenitor cells contributing to skeletal muscle regeneration and sarcoma formation,” Cell Reports, vol. 33, no. 12, article 108535, 2020.
[43] A. Shcherbina, J. Larouche, P. Fraczek et al., “Dissecting murine muscle stem cell aging through regeneration using integrative genomic analysis,” Cell Reports, vol. 32, no. 4, arti- cle 107964, 2020.
[44] Y. Nunez-Alvarez, E. Hurtado, M. Munoz et al., “Loss of HDAC11 accelerates skeletal muscle regeneration in mice,” The FEBS Journal, vol. 288, no. 4, pp. 1201–1223, 2021.
[45] D. A. Wang, Q. Z. Li, and D. M. Jia, “Low-frequency electrical stimulation promotes satellite cell activities to facilitate muscle regeneration at an early phase in a rat model of muscle strain,” BioMed Research International, vol. 2021, Article ID 4218086, 8 pages, 2021.
[46] X. Chen, J. Yuan, G. Xue et al., “Translational control by DHX36 binding to 5’UTR G-quadruplex is essential for mus- cle stem-cell regenerative functions,” Nature Communications, vol. 12, no. 1, p. 5043, 2021.
[47] D. Ratnayake, P. D. Nguyen, F. J. Rossello et al., “Macrophages provide a transient muscle stem cell niche via NAMPT secre- tion,” Nature, vol. 591, no. 7849, pp. 281–287, 2021.
[48] C. S. Fry, J. D. Lee, J. Mula et al., “Inducible depletion of satel- lite cells in adult, sedentary mice impairs muscle regenerative capacity without affecting sarcopenia,” Nature Medicine, vol. 21, no. 1, pp. 76–80, 2015.
[49] A. Cerquone Perpetuini, A. D. Re Cecconi, M. Chiappa et al., “Group I Paks support muscle regeneration and counteract cancer-associated muscle atrophy,” Journal of Cachexia, Sarco- penia and Muscle, vol. 9, no. 4, pp. 727–746, 2018.
[50] K. Kowalski, M. Dos Santos, P. Maire, M. A. Ciemerych, and E. Brzoska, “Induction of bone marrow-derived cells myogenic identity by their interactions with the satellite cell niche,” Stem Cell Research & Therapy, vol. 9, no. 1, p. 258, 2018.